YCBD:NYE-cbdMD Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 0.492

Change

-0.05 (-9.23)%

Market Cap

USD 1.92M

Volume

0.03M

Analyst Target

USD 5.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, hempMD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, drink mixes, and sleep, focus, and calming aids. The company also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name; nootropic mushroom line under the ATRx brand; and hemp derived solutions under the hempMD brand. It distributes its products through its e-commerce website, third-party e-commerce sites, select distributors and marketing partners, wholesalers, and various brick and mortar retailers in the United States. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. is headquartered in Charlotte, North Carolina.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+0.77 (+0.39%)

USD 83.17B
HLN Haleon plc

-0.10 (-0.94%)

USD 47.33B
TAK Takeda Pharmaceutical Co Ltd A..

-0.03 (-0.20%)

USD 46.60B
RDY Dr. Reddy’s Laboratories Ltd..

-0.74 (-0.93%)

USD 13.37B
CTLT Catalent Inc

-0.03 (-0.05%)

USD 10.83B
ELAN Elanco Animal Health

+0.36 (+2.52%)

USD 7.15B
BHC Bausch Health Companies Inc

+0.84 (+11.70%)

USD 2.95B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.12 (-1.36%)

USD 2.70B
CPHI China Pharma Holdings Inc

N/A

USD 3.94M
PBH Prestige Brand Holdings Inc

-0.02 (-0.03%)

N/A

ETFs Containing YCBD

PSY 0.00 % 0.76 %

N/A

N/A
MJUS Amplify ETF Trust 0.00 % 0.00 %

-0.01 (-0.66%)

USD 0.15B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -52.69% 14% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -52.69% 14% F 2% F
Trailing 12 Months  
Capital Gain -57.59% 13% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.59% 13% F 2% F
Trailing 5 Years  
Capital Gain -99.77% 7% C- N/A F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.77% 7% C- N/A F
Average Annual (5 Year Horizon)  
Capital Gain -19.21% 19% F 4% F
Dividend Return -19.21% 19% F 3% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 168.48% 13% F 4% F
Risk Adjusted Return -11.40% 38% F 18% F
Market Capitalization 1.92M 10% F 1% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector